Plasma cfRNA Biomarkers for Early Parkinson's Disease Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Parkinson's disease (PD) are inadequate for early-stage diagnosis and differentiation from other neurodegenerative diseases, lacking definitive molecular biomarkers, leading to misdiagnosis and heterogeneity in clinical presentation.
Innovation Solution
Utilization of plasma cell-free RNA (cfRNA) transcripts as non-invasive biomarkers, employing a predictive model based on Kullback-Leibler divergence and L2 regularization linear model to measure and analyze cfRNA levels for PD diagnosis and differentiation from other neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (patient history and physical examination) are used for PD diagnosis, then the diagnostic process is simple and non-invasive, but the diagnostic accuracy is insufficient and cannot provide definitive diagnosis in early stages
Solution Approach 1:
The patent introduces plasma cell-free RNA transcripts as an intermediary biomarker that bridges the gap between simple clinical examination and complex neuropathological analysis. These cfRNA transcripts serve as a non-invasive mediator that carries molecular information from the brain to accessible blood plasma, enabling accurate PD diagnosis without requiring direct brain tissue examination or complex imaging procedures
Solution Approach 2:
The patent replaces the mechanical and invasive approach of neuropathological analysis (requiring brain tissue examination after death) with a molecular biology-based liquid biopsy approach. By detecting specific cfRNA transcripts in plasma using molecular techniques, the system substitutes the need for physical tissue examination while achieving comparable or superior diagnostic accuracy
2Measurement precision
If imaging methods (DaT SPECT, PET scan) are used to detect dopaminergic neuron damage, then early signs of PD can be detected, but these methods are not definitive for diagnosis and involve complex procedures
Solution Approach 1:
The patent extracts the diagnostic information from complex imaging procedures and concentrates it into specific molecular markers (cfRNA transcripts) that can be measured in plasma. By taking out the essential diagnostic signal (presence of specific RNA transcripts indicating dopaminergic neuron damage) and separating it from the complex imaging procedure, the system achieves equivalent diagnostic power with a simpler, more accessible test
Solution Approach 2:
The patent changes the measurement parameter from imaging-based metrics (radioactive tracer distribution, metabolic activity) to molecular concentration measurements of specific cfRNA transcripts. This parameter change transforms the diagnostic approach from detecting physiological changes in the brain to detecting molecular signatures in blood plasma, achieving similar diagnostic accuracy with a less complex procedure
3Measurement precision
If CSF biomarkers (α-synuclein levels) are measured to differentiate PD from healthy controls, then molecular diagnosis is possible, but results vary due to clinical heterogeneity, cross-contamination with blood, or experimental differences
Solution Approach 1:
The patent uses plasma as an intermediary fluid that is more accessible and less prone to contamination than CSF. By detecting cfRNA transcripts in plasma rather than CSF, the system eliminates the risk of blood-CSF barrier disruption and cross-contamination while maintaining the ability to detect PD-specific molecular signatures. Plasma serves as a stable, accessible mediator that reliably carries brain-derived RNA transcripts
Solution Approach 2:
The patent segments the diagnostic approach by focusing on specific cfRNA transcripts from dopaminergic neurons rather than measuring overall α-synuclein protein levels in CSF. This segmentation allows for more precise and specific detection of PD-related molecular changes, reducing the impact of clinical heterogeneity and experimental variability that affect bulk protein measurements
4Reliability
If no molecular biomarkers are available for PD, then current diagnosis relies on clinical presentation, but this leads to misdiagnosis with error rates of 15% to 24% and cannot differentiate PD from other neurodegenerative diseases
Solution Approach 1:
The patent creates a universal molecular diagnostic system using cfRNA transcripts that can simultaneously diagnose PD, differentiate it from other neurodegenerative diseases, and potentially serve multiple diagnostic functions. The same plasma cfRNA analysis platform can identify PD-specific transcripts, distinguish PD from Alzheimer's and other conditions, and provide a unified molecular basis for diagnosis across different clinical presentations, eliminating the need for multiple separate diagnostic tests
Data Source
AI summary
Methods and systems for detecting, treating, and monitoring Parkinson's Disease (PD), as well as for differentiating PD from non-PD neurodegenerative diseases are provided. Methods include providing a biological sample from the subject; measuring a level of at least one plasma cell-free RNA (cfRNA) transcript in the biological sample; and determining a treatment for the subject based on the level of the at least one plasma cfRNA transcript. In some embodiments, the method further includes: determining a PD severity level based on the level of the at least one plasma cfRNA transcript; and determining the treatment for the subject further based on the PD severity level. Also provided are prediction models for identifying Parkinson's Disease in a subject in need thereof.